Elemer Piros
Stock Analyst at Rodman & Renshaw
(3.21)
# 899
Out of 4,814 analysts
110
Total ratings
35.58%
Success rate
3.17%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BTAI BioXcel Therapeutics | Initiates: Buy | $65 | $1.71 | +3,701.17% | 1 | Mar 19, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $1.38 | +769.57% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $1.15 | +1,378.26% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $1.03 | +967.96% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $40.49 | +23.49% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $0.88 | +1,842.86% | 1 | Sep 30, 2024 | |
| ATHA Athira Pharma | Initiates: Buy | $22 | $0.25 | +8,700.00% | 1 | Aug 19, 2024 | |
| SAVA Cassava Sciences | Reiterates: Buy | $107 | $1.46 | +7,228.77% | 1 | Aug 8, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $0.36 | +3,750.39% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.36 | +4,844.65% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $2.32 | +1,757.45% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.70 | +215.79% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.77 | +872.13% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $1.43 | +952.63% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $21 | $5.65 | +272.01% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $3.39 | +1,022.60% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $1.43 | +2,697.20% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.61 | +715.39% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $114 | $7.24 | +1,474.59% | 3 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $3.02 | +6,522.52% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.41 | +574.49% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $9.17 | +259.87% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $18.04 | +121.73% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $40 | $0.92 | +4,247.35% | 3 | Jan 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.73 | +2,038.73% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $3.51 | +812.98% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $11.00 | +600.32% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $0.74 | +9,382.53% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.31 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $12.08 | +313.91% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $2.24 | +1,373.21% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $10.46 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $6.68 | +289.22% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $161.93 | -82.71% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $4.92 | +17,176.42% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $7.61 | +175.95% | 2 | Jul 12, 2017 |
BioXcel Therapeutics
Mar 19, 2025
Initiates: Buy
Price Target: $65
Current: $1.71
Upside: +3,701.17%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $1.38
Upside: +769.57%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $1.15
Upside: +1,378.26%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $1.03
Upside: +967.96%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $40.49
Upside: +23.49%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $0.88
Upside: +1,842.86%
Athira Pharma
Aug 19, 2024
Initiates: Buy
Price Target: $22
Current: $0.25
Upside: +8,700.00%
Cassava Sciences
Aug 8, 2024
Reiterates: Buy
Price Target: $107
Current: $1.46
Upside: +7,228.77%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $0.36
Upside: +3,750.39%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.36
Upside: +4,844.65%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $2.32
Upside: +1,757.45%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $5.70
Upside: +215.79%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.77
Upside: +872.13%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.43
Upside: +952.63%
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $5.65
Upside: +272.01%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $3.39
Upside: +1,022.60%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $1.43
Upside: +2,697.20%
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.61
Upside: +715.39%
Jun 20, 2023
Reiterates: Buy
Price Target: $114
Current: $7.24
Upside: +1,474.59%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $3.02
Upside: +6,522.52%
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $3.41
Upside: +574.49%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $9.17
Upside: +259.87%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $18.04
Upside: +121.73%
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $0.92
Upside: +4,247.35%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.73
Upside: +2,038.73%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $3.51
Upside: +812.98%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $11.00
Upside: +600.32%
Oct 12, 2020
Initiates: Buy
Price Target: $70
Current: $0.74
Upside: +9,382.53%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.31
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $12.08
Upside: +313.91%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $2.24
Upside: +1,373.21%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $10.46
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $6.68
Upside: +289.22%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $161.93
Upside: -82.71%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $4.92
Upside: +17,176.42%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $7.61
Upside: +175.95%